A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer - Concepedia

Concepedia

Publication | Closed Access

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

30

Citations

16

References

2009

Year

Margie Gerena-Lewis, Jeffrey Crawford, Philip Bonomi, Ann Marie Maddox, John D. Hainsworth, David McCune, Rakesh Shukla, Haoyue Zeigler, Paul E. Hurtubise, Tracy R. Chowdhury,

American Journal of Clinical Oncology

Abstract

Denileukin diftitox at current dose schedule has limited activity in patients with previously treated NSCLC, manifested by disease control without impact on survival.

References

	Year	Citations
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, New England Journal of Medicine	2005	5.4K
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Frank V. Fossella, Russell F. DeVore, Ronald N. Kerr, Journal of Clinical Oncology	2000	1.4K
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. E.Y. Woo, Christina Chu, Theresa J. Goletz, PubMed Cancer ImmunosurveillanceRegulatory Cd4T CellsLate-stage Ovarian CancerImmunology	2001	1.1K
Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation Edward Y. Woo, Heidi Yeh, Christina Chu, The Journal of Immunology	2002	696
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. Frank V. Fossella, J S Lee, Dongjun Shin, Journal of Clinical Oncology	1995	257
Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor. R J Robb, W C Greene The Journal of Experimental Medicine ImmunologyImmune RegulationBeta ChainBound Il-2Immunologic Mechanism	1987	232
DAB389IL-2 (Denileukin Diftitox, ONTAK): A New Fusion Protein Technology Francine M. Foss Clinical Lymphoma CytokineImmunologyDenileukin DiftitoxCell DeathImmunotherapy	2000	56
Differential expression of interleukin‐2 receptors (α and β chain) in mature lymphoid neoplasms Kazunori Nakase, Kenkichi Kita, K Nasu, American Journal of Hematology	1994	50
Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells Tetsuyuki Kiyokawa, Diane P. Williams, Catherine E. Snider, Protein Engineering Design and Selection	1991	48
Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma E. Tisi, P. Lissoni, M Angeli, Cancer Early RecurrenceCancer ImmunosurveillanceIl-2 AvailabilityAdvanced Lung DiseaseMedicine	1992	41

Page 1